



CELL LAB Rat Anti-Mouse CD22

<u>Cat. No.</u>	<u>Form</u>	<u>Quantity</u>
732071	Purified (UNLB) Antibody	0.5 mg
732072	Fluorescein (FITC) Conjugate	0.5 mg
732073	Biotin (BIOT) Conjugate	0.5 mg
732074	Phycoerythrin (PE) Conjugate	0.1 mg
732075	Allophycocyanin (APC) Conjugate	0.1 mg
732076	Spectral Red™ (SPRD) Conjugate	0.1 mg

For Laboratory Use Only

DESCRIPTION

Clone: 2D6
Isotype: Rat IgG1 κ
Specificity: CD22 (Mr 150 kDa), a B lymphocyte adhesion molecule

CD22, also known as Lyb-8, is a heterodimeric transmembrane glycoprotein and a member of a structurally related group of immunoglobulin (Ig) superfamily domain-containing proteins called the sialoadhesin family. It is detected in the cytoplasm early in B cell development (late pro-B cell stage), appears on the cell surface concomitant with IgD, and is found on most IgM⁺IgD⁺ mature B lymphocytes. Expression is lost with terminal differentiation of B cells and is absent on plasma cells. Activation of B cells via cross-linking of surface Ig increases CD22 expression.^{1,2} CD22 associates with the B cell receptor (BCR) complex and mediates intercellular adhesion.²⁻⁴ Its intracellular domain is phosphorylated after antigen receptor cross-linking and is involved in negative regulation of B-cell activation.⁵⁻⁸

APPLICATIONS

- Flow cytometry²
- Blocking of B cell homotypic adhesion²

CHARACTERIZATION

To ensure lot-to-lot consistency, each batch of product is tested to conform with characteristics of a standard reference reagent using flow cytometry.

WORKING DILUTIONS

Flow Cytometry:

FITC conjugate	≤1 μg/10 ⁶ cells
BIOT conjugate	≤1 μg/10 ⁶ cells
PE conjugate	≤0.2 μg/10 ⁶ cells
APC conjugate	≤0.2 μg/10 ⁶ cells
SPRD conjugate	≤0.2 μg/10 ⁶ cells

Other Applications: Since applications vary, determine the optimum working dilution of the product that is appropriate for your specific needs.

HANDLING AND STORAGE

- The purified (UNLB) antibody is supplied as 0.5 mg of purified immunoglobulin in 1.0 mL of 100 mM borate buffered saline, pH 8.0. No preservatives or amine-containing buffer salts added.
- The fluorescein (FITC) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN₃.
- The biotin (BIOT) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN₃.
- The phycoerythrin (PE) and allophycocyanin (APC) conjugates are supplied as 0.1 mg in 1.0 mL of PBS/NaN₃ and a stabilizing agent.
- The Spectral Red (SPRD) conjugate is supplied as 0.1 mg in 1.0 mL of PBS/NaN₃ and a stabilizing agent.
- Protect fluorochrome-conjugated forms from light. Do not freeze.
- Reagent is stable until the expiration date on the vial when stored at 2-8°C.

STATEMENT OF WARNINGS

1. Specimens, samples and all material coming in contact with them should be handled as if capable of transmitting infection and disposed of with proper precautions.
2. Never pipet by mouth and avoid contact of samples with skin and mucous membranes.
3. Do not use reagent beyond the expiration date on the vial label.
4. Minimize exposure of reagent to light during storage or incubation.
5. Avoid microbial contamination of reagent or erroneous results may occur.
6. Use Good Laboratory Practice (GLP) when handling this reagent.
7. Harmful if swallowed.
8. After contact with skin, wash immediately with plenty of water.
9. Contains sodium azide. Sodium azide under acidic conditions yields hydrazoic acid, an extremely toxic compound. Azide compounds should be flushed with running water while being discarded. These precautions are recommended to avoid deposits in metal piping in which explosive conditions can develop. If skin or eye contact occurs, immediately wash excessively with water.

TRADEMARKS

The Beckman Coulter logo is a trademark of Beckman Coulter, Inc.

Spectral Red is a trademark of Southern Biotechnology Associates, Inc.

Cy5 is a trademark of GE Healthcare, Inc.

For additional information or if damaged product is received, contact your local Beckman Coulter Representative.

Spectral Red is a PE/CyTM5 tandem conjugate. Cy5 is for non-commercial research use only, not for therapeutic or in vivo applications. Other use needs license from Amersham Biosciences Corp., under U.S. Patent Nos. 4,981,977 and 5,268,486 and other patents pending. This material (or portions of this material) is subject to proprietary rights of Amersham Biosciences Corp. and Carnegie Mellon University and made and sold under license from Amersham Biosciences Corp. This product is licensed for sale only for research. It is not licensed for any other use. There is no implied license hereunder for any commercial use. Commercial use shall include: 1) sale, lease, license or other transfer of the material or any material derived or produced from it 2) sale, lease, license or other grant of rights to use this material or any material derived or produced from it 3) use of this material to perform services for a fee for third parties. If you require a commercial license to use this material and do not have one, return this material, unopened to Beckman Coulter, Inc. 11800 SW 147 Ave. Miami, FL 33196, USA and any money paid for the material will be refunded.

REFERENCES

1. Symington FW, Subbarao B, Mosier DE and Sprent J. 1982. Lyb-8.2: A new B cell antigen defined and characterized with a monoclonal antibody. *Immunogenetics*, 16:381-391.
2. Torres RM, Law CL, Santos-Argumedeo L, Kirkham PA, Grabstein K, Parkhouse RM and Clark EA. 1992. Identification and characterization of the murine homologue of CD22, a B lymphocyte-restricted adhesion molecule. *J Immunol*, 149:2641-2649.
3. Erickson LD, Tygrett LT, Bhatia SK, Grabstein KH and Waldschmidt TJ. 1996. Differential expression of CD22 (Lyb8) on murine B cells. *Int Immunol*, 8:1121-1129.

4. Law CL, Aruffo A, Chandran KA, Doty RT and Clark EA. 1995. Ig domains 1 and 2 of murine CD22 constitute the ligand-binding domain and bind multiple sialylated ligands expressed on B and T cells. *J Immunol*, 155:3368-3376.
5. Pezzutto A, Rabinovitch PS, Dorken B, Moldenhauer G and Clark EA. 1988. Role of the CD22 human B cell antigen in B cell triggering by anti-immunoglobulin. *J Immunol*, 140:1791-1795.
6. Doody GM, Justement LB, Delibrias CC, Matthews RJ, Lin J, Thomas ML and Fearon DT. 1995. A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. *Science*, 269:242-244.
7. Law CL, Sidorenko SP, Chandran KA, Zhao Z, Shen SH, Fischer EH and Clark EA. 1996. CD22 associates with protein tyrosine phosphatase 1C, Syk, and phospholipase C-gamma (1) upon B cell activation. *J Exp Med*, 183:547-560.
8. O'Keefe TL, Williams GT, Davies SL and Neuberger MS. 1996. Hyperresponsive B cells in CD22-deficient mice. *Science*, 274:798-801.



Manufactured for:
Beckman Coulter, Inc.
4300 N. Harbor Blvd.
Fullerton, CA 92835
www.beckmancoulter.com

Printed in USA
Made in USA

© 2005 Beckman Coulter, Inc.
All Rights Reserved.

PN 733922-A